This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Arany, I.
Right arrow Articles by Slade, H. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Arany, I.
Right arrow Articles by Slade, H. B.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Genital Warts

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, July 2000, p. 1869-1873, Vol. 44, No. 7
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Correlation between Pretreatment Levels of Interferon Response Genes and Clinical Responses to an Immune Response Modifier (Imiquimod) in Genital Warts

I. Arany,1,* S. K. Tyring,1,2 M. M. Brysk,1,2 M. A. Stanley,3 M. A. Tomai,4 R. L. Miller,4 M. H. Smith,4 D. J. McDermott,4 and H. B. Slade4

Departments of Microbiology and Immunology1 and Dermatology,2 University of Texas Medical Branch, Galveston, Texas; Department of Pathology, University of Cambridge, Cambridge, United Kingdom3; and 3M Pharmaceuticals, St. Paul, Minnesota4

Received 13 December 1999/Returned for modification 13 March 2000/Accepted 25 April 2000

Imiquimod (IQ) has been successfully used in treatment of genital warts. In clinical settings, patients responded well but wart reduction rates varied. Our aim was to find a correlation between clinical responses and pretreatment (constitutive) levels of genes that might be involved in the molecular action of IQ. Since IQ is a cytokine inducer, we analyzed levels of expression of genes of the JAK/STAT signaling pathway and their inhibitors as well as interferon response factors (IRFs) in pretreatment biopsy specimens from complete responders (99 to 100% wart reduction rate) versus incomplete responders (75 to 92% wart reduction rate) by reverse transcription-PCR. We found that mRNA levels of signal transducer and activator of transcription 1 (STAT1) and IRF1 were higher in complete responders than in incomplete responders. Incomplete responders expressed larger amounts of STAT3, IRF2, and protein inhibitor of activated STAT1 (PIAS1) mRNAs compared to complete responders before IQ treatment. We hypothesize that high-level expression of STAT1 and IRF1 is advantageous for a better IQ response. The observed differences in constitutive mRNA levels of these genes may be the consequence of alterations in cellular differentiation and/or variable expression of endogenous interferons. Previous in vitro studies showed that keratinocyte differentiation coordinates the balance between positive and negative signals along the JAK/STAT pathway by regulating the IRF1:IRF2 and STAT1:PIAS1 ratios and thus affecting induction of IQ-inducible genes. Specifically, differentiation supports constitutive expression of STAT1 and IRF1 mRNAs but not expression of IRF2 and PIAS1. Our data are in good agreement with studies that showed the importance of STAT1 in cytokine induction and activation of interferon-responsive genes by IQ.

* Corresponding author. Mailing address: Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555-1070. Phone: (409) 772-8145. Fax: (409) 747-6869. E-mail: iarany{at}utmb.edu.

Antimicrobial Agents and Chemotherapy, July 2000, p. 1869-1873, Vol. 44, No. 7
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Wang, Y., Abel, K., Lantz, K., Krieg, A. M., McChesney, M. B., Miller, C. J. (2005). The Toll-Like Receptor 7 (TLR7) Agonist, Imiquimod, and the TLR9 Agonist, CpG ODN, Induce Antiviral Cytokines and Chemokines but Do Not Prevent Vaginal Transmission of Simian Immunodeficiency Virus When Applied Intravaginally to Rhesus Macaques. J. Virol. 79: 14355-14370 [Abstract] [Full Text]  
  • Urosevic, M., Dummer, R., Conrad, C., Beyeler, M., Laine, E., Burg, G., Gilliet, M. (2005). Disease-Independent Skin Recruitment and Activation of Plasmacytoid Predendritic Cells Following Imiquimod Treatment. JNCI J Natl Cancer Inst 97: 1143-1153 [Abstract] [Full Text]  
  • Brown, V. L., Atkins, C. L., Ghali, L., Cerio, R., Harwood, C. A., Proby, C. M. (2005). Safety and Efficacy of 5% Imiquimod Cream for the Treatment of Skin Dysplasia in High-Risk Renal Transplant Recipients: Randomized, Double-blind, Placebo-Controlled Trial. Arch Dermatol 141: 985-993 [Abstract] [Full Text]  
  • Urosevic, M., Oberholzer, P. A., Maier, T., Hafner, J., Laine, E., Slade, H., Benninghoff, B., Burg, G., Dummer, R. (2004). Imiquimod Treatment Induces Expression of Opioid Growth Factor Receptor: A Novel Tumor Antigen Induced by Interferon-{alpha}?. Clin. Cancer Res. 10: 4959-4970 [Abstract] [Full Text]  
  • Urosevic, M., Maier, T., Benninghoff, B., Slade, H., Burg, G., Dummer, R. (2003). Mechanisms Underlying Imiquimod-Induced Regression of Basal Cell Carcinoma In Vivo. Arch Dermatol 139: 1325-1332 [Abstract] [Full Text]  
  • Wang, E., Miller, L. D., Ohnmacht, G. A., Mocellin, S., Perez-Diez, A., Petersen, D., Zhao, Y., Simon, R., Powell, J. I., Asaki, E., Alexander, H. R., Duray, P. H., Herlyn, M., Restifo, N. P., Liu, E. T., Rosenberg, S. A., Marincola, F. M. (2002). Prospective Molecular Profiling of Melanoma Metastases Suggests Classifiers of Immune Responsiveness. Cancer Res. 62: 3581-3586 [Abstract] [Full Text]  
  • Dockrell, D. H., Kinghorn, G. R. (2001). Imiquimod and resiquimod as novel immunomodulators. J Antimicrob Chemother 48: 751-755 [Abstract] [Full Text]  
  • Moisan, J., Wojciechowski, W., Guilbault, C., Lachance, C., Di Marco, S., Skamene, E., Matlashewski, G., Radzioch, D. (2001). Clearance of Infection with Mycobacterium bovis BCG in Mice Is Enhanced by Treatment with S28463 (R-848), and Its Efficiency Depends on Expression of Wild-Type Nramp1 (Resistance Allele). Antimicrob. Agents Chemother. 45: 3059-3064 [Abstract] [Full Text]  
  • Diaz-Arrastia, C., Arany, I., Robazetti, S. C., Dinh, T. V., Gatalica, Z., Tyring, S. K., Hannigan, E. (2001). Clinical and Molecular Responses in High-Grade Intraepithelial Neoplasia Treated with Topical Imiquimod 5%. Clin. Cancer Res. 7: 3031-3033 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»